Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer
- 628 Downloads
Male breast cancer (MBC) is a rare malignant disease, accounting for <1 % of all breast cancers (BCs). Treatment of men with early-stage BC is based on standards established in female BC. Prognostic or predictive markers to guide therapeutic decisions, in particular in early-stage male BC, are missing. Here, we explored whether disseminated tumor cells (DTC) in bone marrow (BM) and circulating tumor cells (CTC) in blood could be suitable biomarkers in male BC.
Patients and methods
Five male patients (pT2–4, pN0–2, M0) with hormone receptor-positive, HER2-negative, and ductal primary BC (median age 70 years, range 51–73) were enrolled in a prospective study of patients with early-stage breast cancer. Here, we analyze the male subgroup. DTC in BM were analyzed before therapy and identified by immunocytochemistry using the pancytokeratin antibody A45B/B3. Blood samples (10 ml) were analyzed for CTC using the AdnaTest BreastCancer (AdnaGen AG, Langenhagen, Germany).
DTC were found in three out of five male patients (60 %) with two DTC detected in one patient and one DTC detected in each of the other two patients. This is compared to a detection rate of 25–40 % in pooled analyses of female patients. CTC were only found in one of five patients. After a median follow-up time of 3 years (range 1–10 years), all patients were still alive and free of relapse.
The prevalence of DTC and CTC in male BC seems comparable with female BC. No prognostic relevance could be documented in this small population. A prospective study or at least larger cases series will be required to assess the prognostic or predictive value of DTC and CTC in this rare disease.
KeywordsMale breast cancer Early-stage breast cancer Disseminated tumor cells Circulating tumor cells
Circulating tumor cells
Disseminating tumor cells
Male breast cancer
Conflict of interest
The authors declare that they have no competing interests.
- Aktas B, Müller V, Schumacher K, Tewes M, Zeitz J, Kasimir-Bauer S, Rack B, Janni W, Solomayer E, Fehm T, behalf of the DETECT study group (2011) Comparison of ER and PR status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 122(2):356–360PubMedCrossRefGoogle Scholar
- Banys M, Solomayer EF, Gebauer G, Janni W, Krawczyk N, Lueck HJ, Becker S, Huober J, Kraemer B, Wackwitz B, Hirnle P, Wallwiener D, Fehm T (2013) Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer 15(13):480. doi: 10.1186/1471-2407-13-480 CrossRefGoogle Scholar
- Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen PB, Dirix LY (2006) Real-time RT-PCR detection of disseminated tumor cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94:672–680PubMedCentralPubMedGoogle Scholar
- Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K (1999) Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells: The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Cytotherapy 5:377–388CrossRefGoogle Scholar
- Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber G, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRefGoogle Scholar
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M Boyle P (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publications, Lyon, IARCGoogle Scholar
- Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA (2003) Invasive breast carcinoma. In: von Devilee P, Tavassoli FA (eds) World Health Organization classification of tumours. Tumours of the breast and female genital organs. IARC Press, Lyon, pp 13–59Google Scholar
- Fehm T, Braun S, Müller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K (2006) A concept for the standardized detection of disseminated tumor cells in bone marrow of patients with primary breast cancer and its clinical implementation. Cancer 197:885–892CrossRefGoogle Scholar
- Fehm T, Hoffmann O, Aktas B, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11:R59PubMedCentralPubMedCrossRefGoogle Scholar
- Janni W, Vogl FD, Wiedswang G, Synnestved M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 17(9):2967–2976PubMedCrossRefGoogle Scholar
- Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B (2004) Her-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121:631–636PubMedCrossRefGoogle Scholar
- Mathiesen RR, Borgen E, Renolen A, Lokkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lonning PE, Naume B (2012) Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 14(4):R117PubMedCentralPubMedCrossRefGoogle Scholar
- Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogenous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678–3685PubMedCrossRefGoogle Scholar
- Pierga JY, Bonneton Ch, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392–1400PubMedCrossRefGoogle Scholar
- Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA (2011) Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and SD44 (+)CD24((lo) cancer stemm cell phenotype. Eur J Cancer 47:1527–1536PubMedCentralPubMedCrossRefGoogle Scholar
- Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 00:1–9Google Scholar
- Solomayer EF, Gebauer G, Hirnle P (2008) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 69(2):170–171Google Scholar
- Strathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20:3404–3412CrossRefGoogle Scholar
- Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou E, Stathopoulos S, Georgoulias V, Mavraudis D (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24:3756–3762PubMedCrossRefGoogle Scholar
- Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapie in patients with early breast cancer. J Clin Oncol 27:2177–2184PubMedCrossRefGoogle Scholar